Achillion Pharmaceuticals, Inc. engages in the research and development of small molecule drug therapies for infectious diseases and immune system disorders. It intends to commercialize its anti-viral medicines for the treatment of hepatitis C and resistant bacterial infections. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.
